July 16, 2021 10:40 AM EDTUpdated 04:12 PM

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff

Kathy Wong

Editor

Alex Hoffman

Senior Editor

→ Covid-19 variants have marred the effectiveness of Eli Lilly and AbCellera’s bamlanivimab to such an extent that the US government stopped using the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff

Kathy Wong

Editor

Alex Hoffman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Eli Lil­ly part­ner Ab­Cellera finds a CBO in the face of bam­lanivimab strug­gles; Fi­bro­Gen's next CSO walks in­to rox­adu­s­tat re­buff

Editor

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff